Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 15/20 | 0.39 |
| ▸ | PRKDC | P78527 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29182167 | 0.99 | PDPK1 (0.39) | PDPK1ATRPRKDCCYP3A4HPGDS | |
| SCHEMBL25136435 | 0.86 | PDPK1 (0.43) | PDPK1ATRPRKDC | |
| SCHEMBL30182839 | 0.86 | PDPK1 (0.43) | PDPK1ATRPRKDC | |
| SCHEMBL25136322 | 0.84 | LDLR (0.38) | PDPK1HPGDSIDO1 | |
| Hydrochloric Acid SCHEMBL29182214 | 0.83 | LDLR (0.37) | PDPK1HPGDSIDO1 | |
| SCHEMBL25136318 | 0.82 | PDPK1 (0.39) | PDPK1CYP3A4HPGDSIDO1 | |
| Hydrochloric Acid SCHEMBL29182228 | 0.81 | PDPK1 (0.38) | PDPK1CYP3A4HPGDSIDO1 | |
| SCHEMBL30834341 | 0.77 | DGAT1 (0.40) | PDPK1CYP3A4HPGDSIDO1 | |
| SCHEMBL25136068 | 0.74 | ACVR2A (0.48) | ATR | |
| SCHEMBL25136064 | 0.73 | ATR (0.47) | ATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | PDPK1 2670/4885ATR 3800/4885PRKDC 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.